Loefflers syndrome differential diagnosis: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 11: Line 11:
|- style="background: #4479BA; color: #FFFFFF; text-align: center;"
|- style="background: #4479BA; color: #FFFFFF; text-align: center;"
! colspan="2" rowspan="4" |Diseases
! colspan="2" rowspan="4" |Diseases
| colspan="4" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Clinical manifestations'''
| colspan="2" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Clinical manifestations'''
! colspan="5" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Para-clinical findings
! colspan="5" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Para-clinical findings
| colspan="1" rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Gold standard'''
| colspan="1" rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Gold standard'''
! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Additional findings
! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Additional findings
|-
|-
| colspan="2" rowspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Symptoms'''
| rowspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Symptoms'''
! colspan="2" rowspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Physical examination
! rowspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Physical examination
|-
|-
! colspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Lab Findings
! colspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Lab Findings
Line 36: Line 36:
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Transpulmonary
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Transpulmonary
passage of larvae (Loffler's syndrome)
passage of larvae (Loffler's syndrome)
| colspan="2" style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
* Cough
* Cough
* Sputum production
* Sputum production
*  
*  
| colspan="2" style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
* Wheezing
* Wheezing
* Fever
* Fever
Line 67: Line 67:


eosinophilia
eosinophilia
| colspan="2" style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
* Cough
* Cough
* Breathlessness
* Breathlessness
* Fatigue
* Fatigue
*  
*  
| colspan="2" style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
* Fever.
* Fever.
* Wheezing
* Wheezing
Line 95: Line 95:
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Allergic bronchopulmonary aspergillosis
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Allergic bronchopulmonary aspergillosis
| colspan="2" style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
* '''Repeated episodes of:'''
* '''Repeated episodes of:'''
* Bronchial obstruction, inflammation
* Bronchial obstruction, inflammation
Line 111: Line 111:
* Hemoptysis
* Hemoptysis
* Wheezing
* Wheezing
| colspan="2" style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
* Fever
* Fever
* Crackles
* Crackles
Line 136: Line 136:


helminths
helminths
| colspan="2" style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
* Depends on the organism for example:
* Depends on the organism for example:
* Periorbital edema, myositis, and eosinophilia ('''Trichinellosis)'''
* Periorbital edema, myositis, and eosinophilia ('''Trichinellosis)'''
| colspan="2" style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
* Depends on the organism for example:
* Depends on the organism for example:
* Periorbital edema
* Periorbital edema
Line 167: Line 167:
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Pulmonary parenchymal invasion
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Pulmonary parenchymal invasion
| colspan="2" style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| colspan="2" style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
* Fever
* Fever
* Crackles
* Crackles
Line 189: Line 189:
| rowspan="2" |Nonhelminthic infections
| rowspan="2" |Nonhelminthic infections
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Coccidioidomycosis
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Coccidioidomycosis
| colspan="2" rowspan="2" style="background: #F5F5F5; padding: 5px;" |
| rowspan="2" style="background: #F5F5F5; padding: 5px;" |
* Manifests as a community-acquired pneumonia (CAP) approximately 7 to 21 days after exposure
* Manifests as a community-acquired pneumonia (CAP) approximately 7 to 21 days after exposure
| colspan="2" rowspan="2" style="background: #F5F5F5; padding: 5px;" |
| rowspan="2" style="background: #F5F5F5; padding: 5px;" |
* Fever
* Fever
* Crackles
* Crackles
Line 214: Line 214:
|-
|-
| colspan="2" |Eosinophilic granulomatosis with polyangiitis (Churg-Strauss)
| colspan="2" |Eosinophilic granulomatosis with polyangiitis (Churg-Strauss)
| colspan="2" style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
* Sinusitis
* Sinusitis
* Asthma,  
* Asthma,  
* Skin, cardiovascular, gastrointestinal, renal, and neurologic systems may also be involved.  
* Skin, cardiovascular, gastrointestinal, renal, and neurologic systems may also be involved.  
| colspan="2" style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
* Fever
* Fever
* Crackles
* Crackles
Line 243: Line 243:
|-
|-
| colspan="2" |Drug- and toxin-induced eosinophilic lung diseases
| colspan="2" |Drug- and toxin-induced eosinophilic lung diseases
| colspan="2" style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
* Asymptomatic pulmonary infiltration with eosinophils
* Asymptomatic pulmonary infiltration with eosinophils
* Chronic cough with or without dyspnea, fever, acute eosinophilic pneumonia, and
* Chronic cough with or without dyspnea, fever, acute eosinophilic pneumonia, and
Line 251: Line 251:
* Enlarged lymph nodes
* Enlarged lymph nodes
* History of initiation of a culprit medication two to six weeks prior to disease onset
* History of initiation of a culprit medication two to six weeks prior to disease onset
| colspan="2" style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
* Fever
* Fever
* Crackles
* Crackles
Line 272: Line 272:
|
|
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Chronic eosinophilic pneumonia
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Chronic eosinophilic pneumonia
| colspan="2" style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
* Predominantly in women and nonsmokers
* Predominantly in women and nonsmokers


* Following radiation therapy for breast cancer  
* Following radiation therapy for breast cancer  
* Cough, fever, progressive breathlessness, weight loss, wheezing, and night sweats; asthma accompanies or precedes the illness in 50 percent of cases
* Cough, fever, progressive breathlessness, weight loss, wheezing, and night sweats; asthma accompanies or precedes the illness in 50 percent of cases
| colspan="2" style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
* Fever
* Fever
* Crackles
* Crackles
Line 303: Line 303:
|
|
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Idiopathic acute eosinophilic pneumonia
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Idiopathic acute eosinophilic pneumonia
| colspan="2" style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
* Acute respiratory failure in a previously healthy patient
* Acute respiratory failure in a previously healthy patient
*  
*  
Line 309: Line 309:
* Nonproductive cough
* Nonproductive cough
* Dyspnea,
* Dyspnea,
| colspan="2" style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
* Fever
* Fever
* Crackles
* Crackles
Line 333: Line 333:
|- style="background: #4479BA; color: #FFFFFF; text-align: center;"
|- style="background: #4479BA; color: #FFFFFF; text-align: center;"
! colspan="2" |Diseases
! colspan="2" |Diseases
!Symptom 1
!Symptom  
! colspan="1" rowspan="1" |Symptom 2
!Physical exam  
!Physical exam 1
! colspan="1" rowspan="1" |Physical exam 2
!Increased Eosinophil count  
!Increased Eosinophil count  
(High)
(High)
Line 348: Line 346:
|
|
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Sarcoidosis]]
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Sarcoidosis]]
| colspan="2" style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| colspan="2" style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
* +/- mild fever
* +/- mild fever
* Crackles
* Crackles
Line 369: Line 367:
|
|
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Pulmonary Langerhans cell histiocytosis (Histiocytosis X)
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Pulmonary Langerhans cell histiocytosis (Histiocytosis X)
| colspan="2" style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| colspan="2" style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
* Crackles
* Crackles
* Wheezing
* Wheezing
Line 383: Line 381:
|
|
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Idiopathic pulmonary fibrosis
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Idiopathic pulmonary fibrosis
| colspan="2" style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| colspan="2" style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
* Crackles
* Crackles
| style="background: #F5F5F5; padding: 5px;" |<10 percent
| style="background: #F5F5F5; padding: 5px;" |<10 percent
Line 396: Line 394:
|
|
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Differential Diagnosis 7
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Differential Diagnosis 7
| colspan="2" style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| colspan="2" style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |

Revision as of 15:08, 11 June 2019

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Soroush Seifirad, M.D.[2]

Overview

Loeffler syndrome must be differentiated from other diseases that cause pulmonary eosinophilia, such as Churg-Strauss, drug and toxin-induced eosinophilic lung diseases, other helminthic and fungal infection related eosinophilic lung diseases, and nonhelminthic infections such as Coccidioidomycosis, and Mycobacterium tuberculosis.

Differentiating Loeffler syndrome from other pulmonary eosinophilia syndromes on the basis of etiology.

Diseases Clinical manifestations Para-clinical findings Gold standard Additional findings
Symptoms Physical examination
Lab Findings Imaging Histopathology
Increased Eosinophil

count

Other lab findings CXR CT Scan
Helminthic

and fungal infection-related

eosinophilic lung diseases

Transpulmonary

passage of larvae (Loffler's syndrome)

  • Cough
  • Sputum production
  • Wheezing
  • Fever
  • Crackles
  • Round or oval opacities (several millimeters to several centimeters)
  • In both lungs
  • Generally present when blood eosinophilia exceeds 10%
  • Migratory
  • May become confluent in perihilar areas
  • Generally clear spontaneously
  • Ascaris lumbricoides
  • Hookworms such as:
  • Ancylostoma duodenale
  • Necator americanus)
  • Strongyloides stercoralis
Tropical

pulmonary

eosinophilia

  • Cough
  • Breathlessness
  • Fatigue
  • Fever.
  • Wheezing
  • Crackles
  • 40 to 70 percent (>3000/microL) plus elevated IgE levels ( >1000 units/mL)
  • Diffuse opacities
  • Around 20% of patients have a normal CXR
  • Reticular and small nodular opacities
  • Bronchiectasis
  • Air trapping
  • Calcification
  • Mediastinal adenopathy
  • Wuchereria bancrofti
  • Brugia malayi
Allergic bronchopulmonary aspergillosis
  • Repeated episodes of:
  • Bronchial obstruction, inflammation
  • Mucoid impaction
  • Can lead to:
  • Bronchiectasis
  • Fibrosis
  • Respiratory compromise
  • Clinical picture of ABPA is dominated by underlying asthma (or cystic fibrosis)
  • Bronchial obstruction
  • Fever
  • Malaise,
  • Expectoration of brownish mucous plugs
  • Peripheral blood eosinophilia
  • Hemoptysis
  • Wheezing
  • Fever
  • Crackles
  • Wheezing
Mild to moderate
  • HRCT:
  • Widespread proximal cylindrical bronchiectasis with upper lobe predominance and bronchial wall thickening.
  • Central bronchiectasis with normal tapering of distal bronchi (classic manifestation of ABPA, neither sensitive nor specific)
  • Asthmatic bronchiolitis, eosinophilic pneumonia, bronchocentric granulomatosis, and mucoid impaction of bronchi
  • +/- bronchocentric granulomatosis (pulmonary eosinophilia in the absence of endobronchial fungi)
Heavy

hematogenous

seeding

with

helminths

  • Depends on the organism for example:
  • Periorbital edema, myositis, and eosinophilia (Trichinellosis)
  • Depends on the organism for example:
  • Periorbital edema
  • Tenderness in muscles
  • Fever
  • (Trichinellosis)
Mild to

moderate to

high

  • Trichinellosis: Ab will be positive 2-8 weeks after infection
  • Strongyloides: ELISA is generally positive while stool examination is often negative.
  • Strongyloides: diffuse ground glass opacities
  • Ascarids and hookworms
  • Trichinellosis
  • Disseminated strongyloidiasis
  • Cutaneous and visceral larva migrans
  • Schistosomiasis
  • Prior treatment with glucocorticoids may be a risk factor.
Pulmonary parenchymal invasion
  • Fever
  • Crackles
  • Wheezing
  • Eosinophilia is prominent in the early stages of disease but minimal with established disease
  • Ab testing Useful in later infection with Paragonimus
  • Nodular with surrounding areas of ground glass
  • Peripheral
  • Common in the mid- and lower lung zones
  • Finding eggs in the sputum or bronchoalveolar lavage fluid
  • Helminths such as paragonimiasis
Nonhelminthic infections Coccidioidomycosis
  • Manifests as a community-acquired pneumonia (CAP) approximately 7 to 21 days after exposure
  • Fever
  • Crackles
  • Wheezing
  • Antibody testing may be negative early in the course of disease
Mycobacterium tuberculosis
Eosinophilic granulomatosis with polyangiitis (Churg-Strauss)
  • Sinusitis
  • Asthma,
  • Skin, cardiovascular, gastrointestinal, renal, and neurologic systems may also be involved.
  • Fever
  • Crackles
  • Wheezing
  • 1500 cells/microL
  • > 10 percent of the total leukocyte count
  • Antineutrophil cytoplasmic antibodies (ANCA)
  • Myeloperoxidase (MPO) perinuclear staining pattern
  • Antineutrophil cytoplasmic antibodies (ANCA)
  • Myeloperoxidase (MPO) perinuclear staining pattern
  • Transient and patchy opacities without lobar or segmental distribution
  • lung biopsy:
  • Eosinophilic infiltrates
  • eosinophilic vasculitis (especially of the small arteries and veins)
  • Interstitial and perivascular necrotizing granulomas
  • Areas of necrosis
Drug- and toxin-induced eosinophilic lung diseases
  • Asymptomatic pulmonary infiltration with eosinophils
  • Chronic cough with or without dyspnea, fever, acute eosinophilic pneumonia, and
  • DRESS:
  • Skin eruption
  • Fever, Facial edema
  • Enlarged lymph nodes
  • History of initiation of a culprit medication two to six weeks prior to disease onset
  • Fever
  • Crackles
  • Wheezing
Mild to moderate
  • Medications such as:
  • Nonsteroidal antiinflammatory drugs
  • Phenytoin
  • L-tryptophan
  • Antibiotics (nitrofurantoin, minocycline, sulfonamides, ampicillin, daptomycin)
  • Toxins such as:
  • Aluminum silicate and particulate metals •Sulfite •Scorpion stings •Inhalation of o heroin, crack cocaine, or marijuana •Inhalation of organic chemicals, dust or smoke, during rubber manufacture, fireworks, firefighting, tobacco smoking •Abuse of 1,1,1-trichloroethane (Scotchgard)
Chronic eosinophilic pneumonia
  • Predominantly in women and nonsmokers
  • Following radiation therapy for breast cancer
  • Cough, fever, progressive breathlessness, weight loss, wheezing, and night sweats; asthma accompanies or precedes the illness in 50 percent of cases
  • Fever
  • Crackles
  • Wheezing
  • ≥40 percent
  • Eosinophilia may be absent in 10-20% of patients
  • Bilateral peripheral or pleural-based infiltrates described as the "photographic negative" of pulmonary edema is virtually pathognomonic for the disease (in 33% of cases)
  • Pleural effusion
  • Cavitation
  • BAL eosinophilia ≥25 percent is suggestive of CEP.
  • Nodular bronchial mucosal lesions
  • Necrotizing eosinophilic inflammation
  • Lung biopsy:
  • Interstitial and alveolar eosinophils and histiocytes, including multinucleated giant cells
  • Fibrosis (minimal)
  • Organizing pneumonia (common)
Idiopathic acute eosinophilic pneumonia
  • Acute respiratory failure in a previously healthy patient
  • Acute febrile illness of less than seven days' duration, characterized by:
  • Nonproductive cough
  • Dyspnea,
  • Fever
  • Crackles
  • Wheezing
  • ≥25 percent
  • Non specific but might reveal
  • Diffuse pulmonary opacities on imaging
  • Bronchoalveolar lavage that reveals ≥25 percent eosinophils
  • When the diagnosis is uncertain lung biopsy is recommended:
  • Histopathologic findings include:
  • Diffuse alveolar damage
  • Hyaline membranes
  • Marked numbers of interstitial and lesser numbers of alveolar eosinophils
  • Often associated with recent initiation or resumption of cigarette smoking
  • Less commonly with heavy inhalational exposure to smoke, fine sand, or dust
Diseases Symptom Physical exam Increased Eosinophil count

(High)

Other lab findings CXR CT Scan Histopathology Gold standard Additional findings
Sarcoidosis
  • +/- mild fever
  • Crackles
Mild to moderate
  • Honeycombing
Pulmonary Langerhans cell histiocytosis (Histiocytosis X)
  • Crackles
  • Wheezing
Mild to moderate
Idiopathic pulmonary fibrosis
  • Crackles
<10 percent
Differential Diagnosis 7

References

Template:WH Template:WS